Cancer

View All

Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial
Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Servier Acquires Agios' Cancer Portfolio in a USD 2 Billion Deal The year is a prime witness of pricey deals and acquisitions in the pharmaceutical industry. To leave its mark, another player decided to hop onto the list. French drugmaker Servier has announced the acquisition of the Oncology business of Agios Ph...

Find More

pharma happenings for BMS Sanofi GW Pharmaceuticals Kiadis
Bristol Myers’ psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm’s Xpovio; Kiadis USD 358M Buyout

Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravaci...

Find More

Top-cancers-in-the-world
Top 5 Cancers Creating Major Challenge To The Global Healthcare System

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...

Find More

Neoantigen based Personalized Cancer Therapeutic Vaccines Market
Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines

Neoantigen based Personalized Cancer Therapeutic Vaccines Market is advancing owing to bioinformatics-technological advancements, improved diagnosis, and a strong pipeline. Cancer therapeutic vaccines, unlike prophylactic vaccines, form a therapeutic option for the late-stage cancer patients in which the body’...

Find More

Opioid Withdrawal Syndrome
Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates

The year 2016, around 48.5 million Americans older than 12 years, reported to be actively abusing prescription opioids or involved in illicit drug use, says CDC drug surveillance report. The toll has been increasing and is almost impossible to ignore. It is disheartening to note that between the period between 1999...

Find More

Cardiovascular Disease
Cardiovascular Disease: A major cause of health loss and a global burden

Cardiovascular diseases (CVDs) are one of the leading causes of death and health loss in people in the US. As per a study by the National Vital Statistics Report, every 37 seconds, one person dies of Cardiovascular diseases in the US.  Cardiovascular diseases also known as heart disease, encompasses a wide range...

Find More

First oral GLP-1 treatment approved for type2 Diabetes

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...

Find More

Recent Pharma News
Roche’s Tecentriq combo proves effective in Bladder cancer

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug, Tecentriq, combined with Pt-based chemotherapy showed a noteworthy improvement in patients with untreated advanced bla...

Find More

breast cancer emerging drugs
How HR+/ HER2-Breast Cancer emerging drugs will transform the market?

More than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of them are Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Ph...

Find More

HR+/HER2- Breast Cancer
Global HR+/ HER2- Breast Cancer Market Scenario

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer ce...

Find More